Biocad scores another victory in MAb biosimilars with marketing approval for bevacizumab

Leading Russian biopharmaceutical company Biocad has obtained a marketing authorization from the Russian Ministry of Health for its bevacizumab, a biosimilar of Swiss pharma giant Roche’s (ROG: SIX) Avastin.

Bevacizumab is one of the most expensive therapeutic proteins reimbursed by the Russian government, and is included in the federal list of essential drugs, which regulates pricing strategy in the domestic market and determines the maximal cost of medicinal products.

In Russia the official registered price for 400mg of the originator product by Roche is 61,536 roubles without the VAT, which is equal to $887 at today's exchange rate.  Biocad’s  product will be 30% less expensive and will be available at the price 43,075 or $621.